Cancer Research Institute shared a report by Charlie Schmidt on LinkedIn:
“Can CAR T cell therapy be used to fight prostate cancer?
In a new phase 1 trial, investigators treated 14 metastatic prostate cancer patients who no longer responded to hormonal therapy with 100 million CAR T cells, either with or without lymphodepletion. “Results were encouraging,” Harvard Health Publishing describes, suggesting that CAR T cell therapy “may emerge as an additional immunotherapeutic option for men with prostate cancer.”
Quoting on Charlie Schmidt’s report:
Tittle: CAR-T immunotherapy for prostate cancer? Early clinical trial results suggest new opportunities.
Authors: Charlie Schmidt, Editor, Harvard Medical School Annual Report on Prostate Diseases
Source: Cancer Research Institute/LinkedIn